Wolverine Legal Status, FDA 503A Category, and Compounding Access

Access is under active review — and that is the lead

The most movement on Wolverine legal status in years is happening right now. Both of the blend's components — BPC-157 and TB-500, the thymosin beta-4 fragment LKKTETQ — are on the published agenda of an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[15]. Access to legally compounded peptide preparations could expand depending on how that review unfolds.

That is the forward-leaning part, and it has to be read with a hard boundary around it. A PCAC discussion is a scheduled step in evaluation, not a decision and not a reclassification — it is advisory, and inclusion on a final 503A bulks list is decided by separate FDA rulemaking under the agency's interim compounding policy ^[13][14][15]. No outcome of the July 2026 meeting should be assumed, and no date should be attached to a predicted result. What can be stated today is the present-tense status, which is the next section.

The current FDA status: Category 2, restricted

As of today, both of Wolverine's components are FDA Category 2 bulk drug substances, and compounding-pharmacy access is restricted. This is the present-tense fact, and it is the one that governs ^[12].

The U.S. Federal Food, Drug, and Cosmetic Act governs compounding through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[13]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise the substance must be nominated and evaluated by FDA ^[13].

Under FDA's interim policy, Category 2 bulk drug substances are those nominated with sufficient information to evaluate but that FDA has identified as raising significant safety risks. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[13].

• BPC-157 was identified by FDA as a bulk drug substance that may present significant safety risks and placed in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[12].
• TB-500 is listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the thymosin beta-4 fragment that is the TB-500 leg of this blend — and was likewise placed in Category 2, effective with the September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information ^[12].

Neither component is an FDA-approved drug, and the blend has no approved therapeutic indication ^[12]. There is no component carve-out: both BPC-157 and TB-500 are currently Category 2, and both are under the single scheduled July 23-24, 2026 review ^[12][15].

How legally compounded peptide access works

Legally compounded access in the U.S. follows a defined pathway, and it is worth describing in general terms because it is the framework any future change would operate within. A compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, an FDA-registered 503B outsourcing facility ^[13].

The steps, in order: a patient is evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter; if appropriate and lawful, the prescriber issues a valid prescription; the prescription is dispensed by a 503A pharmacy or sourced from a 503B facility ^[13]. Telehealth is one channel for the prescriber-evaluation step that begins this pathway — a route to a licensed-prescriber consultation, not a separate legal status. It does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription ^[13].

The binding caveat is ingredient eligibility. A compounder may lawfully use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. Ingredients FDA has flagged for significant safety risks — which currently includes both of Wolverine's components — are not eligible for routine 503A compounding while that status stands ^[13]. This page describes the regulatory landscape in general terms. It is not medical or legal advice, names no pharmacy, clinic, or provider, and gives no dosing or administration instructions.

WADA status and the regulatory FAQ

Both constituents are also prohibited in sport by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories ^[11]. The blend is banned in and out of competition for the relevant classes.

Is Wolverine legal?

The Wolverine blend is not an approved product, and its two components are FDA Category 2 bulk substances currently restricted for routine 503A pharmacy compounding ^[12]. Neither BPC-157 nor TB-500 is an FDA-approved drug, and both are prohibited in sport by WADA ^[11][12]. Both components are on the agenda of a July 23-24, 2026 FDA PCAC meeting as candidates for the 503A bulks list — a scheduled review, not a change in current status ^[15].

Can you get BPC-157 from a compounding pharmacy?

As of today, BPC-157 is an FDA Category 2 bulk drug substance, which means it is not within FDA's enforcement-discretion policy for routine 503A compounding while that status stands ^[12][13]. Legally compounded access generally requires a licensed-prescriber evaluation and a valid, patient-specific prescription filled by a 503A pharmacy or 503B facility — but only for ingredients eligible under the bulk-substance rules, which BPC-157 currently is not ^[13]. BPC-157 is on the July 2026 PCAC agenda for evaluation ^[15].

What is the FDA 503A status of Wolverine?

Wolverine has no status of its own — it is a two-peptide blend, not a single substance — but both of its components are FDA Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, on safety-risk grounds ^[12]. Category 2 substances are not covered by FDA's enforcement-discretion policy ^[13]. Both BPC-157 and TB-500 appear on the July 23-24, 2026 PCAC agenda as substances being considered for inclusion on the 503A bulks list — a scheduled evaluation, not a listing decision ^[15].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved therapeutic indication. In 2023 FDA placed BPC-157 in Category 2 — bulk drug substances not eligible for routine 503A compounding pending further evaluation — and the thymosin beta-4 fragment (LKKTETQ) known as TB-500 was placed in Category 2 in the same update ^[12]. Both constituents are prohibited by WADA: BPC-157 under S0, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories ^[11].